Evaluation of the antibiofilm, effects the related mechanisms on colistin-resistant Pseudomonas aeruginosa antibiofilm and colistin-resistant Pseudomonas aeruginosa
Article Sidebar
Main Article Content
Abstract
Pseudomonas aeruginosa is thought to be the third most frequent cause of catheter-associated UTIs. The production of urease greatly increases the effectiveness of catheter blockage caused by biofilm formation. Because biofilms are important virulence factors that make antibiotics less effective, there is an urgent need to develop novel antibiotic substitutes. Urinary tract infections have been mostly linked to Pseudomonas aeruginosa (P. aeruginosa). The final line of treatment for P. aeruginosa infections is colonistin. But when it comes to treating individuals with colistin-resistant (COL-R) P. aeruginosa, colistin is losing its effectiveness. This study looked into how the antibiofilm, characteristics, and underlying mechanisms of COL-R P. aeruginosa. Our results showed that at (62 μg/ml) sub–Minimum Inhibitory Concentration (MIC), colistin showed remarkable biofilm inhibitory outcome in wild type strains of P. aeruginosa that are multidrug resistant. Strong biofilm producer strains were incubated with 1ml of sub-MIC of colistin for 24 and 48 hours at 37C, the colistin was also examined for their ability to inhibit the biofilm-forming P. aeruginosa. colistin-provide an innovative strategy for biomedical therapy of resistant bacteria because of their elevated antibacterial effect, but only for certain purposes.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1.Al-Tawalbeh, D. M., Alawneh, J. M., Momani, W., & Mayyas, A. (2025). Comparative antibacterial activity of clove extract against Pseudomonas aeruginosa. BMC Complementary Medicine and Therapies, 25
2 . Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aerugino Viñes, J., Herrera, S., Vergara, A., Roca, I., Vila, J., Aiello, T. F., ... & Pitart, C. (2025).
3. Elshimy, R., El-Shiekh, R. A., Okba, M. M., Ashour, R., Ibrahim, M. A., Hassanen, E. I., ... & Ali, M. E. (2025). Unveiling the antimicrobial, antivirulence, and wound-healing accelerating potentials of resveratrol against carbapenem-resistant Pseudomonas aeruginosa (CRPA)-septic wound in a murine model. Inflammopharmacology, 33(1), 401-416.
4. Papacostas, G., Grant, G. D., & Hall, S. (2024). Risk of Pseudomonas aeruginosa antimicrobial resistance using time series analysis of antibiotic usage. Journal of Pharmacy Practice and Research.
5. Sher, E. K., Džidić-Krivić, A., Sesar, A., Farhat, E. K., Čeliković, A., Beća-Zećo, M., ... & Sher, F. (2024). Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections. Pharmacology & Therapeutics, 108688.
6. Timm, M. R., Russell, S. K., & Hultgren, S. J. (2024). Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics. Nature Reviews Microbiology, 1-15.
7. Flores-Vega, V. R., Partida-Sanchez, S., Ares, M. A., Ortiz-Navarrete, V., & Rosales-Reyes, R. (2025). High-risk Pseudomonas aeruginosa clones harboring β-lactamases: 2024 update. Heliyon, 11(1).
8. Macesic, N., Uhlemann, A. C., & Peleg, A. Y. (2025). Multidrug-resistant Gram-negative bacterial infections. The Lancet, 405(10474), 257-272.
9. Li, N., Ebrahimi, E., Sholeh, M., Dousti, R., & Kouhsari, E. (2025). A systematic review and meta‐analysis: rising prevalence of colistin resistance in ICU‐acquired Gram‐negative bacteria. APMIS, 133(1), e13508.
10. Rojek, S. W., Wojtowicz, I., Taccone, F. S., & Duszynska, W. (2025). Colistin Use for the Treatment of Multi-Drug-Resistant Gram-Negative Severe Infections in ICU Patients: A Single-Center Study. Journal of Clinical Medicine, 14(3), 797.
11.Cordisco, E., & Serra, D. O. (2025). Moonlighting antibiotics: the extra job of modulating biofilm formation. Trends in Microbiology.
12. Erkihun, M., Asmare, Z., Endalamew, K., Getie, B., Kiros, T., & Berhan, A. (2024). Medical scope of biofilm and quorum sensing during biofilm formation: Systematic review. Bacteria, 3(3), 118-135.
13. Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Cirković I, et al. Quantification of biofilm in microtiter plates: Overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS (2007); 115:891‑9. DOI: 10.1111/j.1600-0463.2007.apm_630.x)
14. [Dortet L, Broda A, Bernabeu S, Glupczynski Y, Bogaerts P, Bonnin R, et al. Optimization of the MALDIxin test for the rapid identification of colistin resistance in Klebsiella pneumoniae using MALDI-TOF MS. J Antimicrob Chemother. 2020;75(1):110–6. https://doi.org/10.1093/jac/dkz405.].
15. [Romi, Z. M., & Ahmed, M. E. (2024). The Influence of Biologically Synthesized Copper Nanoparticles on the Biofilm Produced by Staphylococcus haemolyticus 1solated from Seminal Fluid. Iraqi Journal of Science, 1948-1968.].
16. Cortesia C, Vilcheze C, Bernut A, Contreras W, Gomez K, de Waard J, et al. Acetic Acid, the active component of vinegar, is an effective tuberculocidal disinfectant. mBio. 2014;5(2):e00013–14. https:// doi. org/ 10. 1128/ mBio. 00013- 14.
17. El Husseini, N., Carter, J. A., & Lee, V. T. (2024). Urinary tract infections and catheter-associated urinary tract infections caused by Pseudomonas aeruginosa. Microbiology and Molecular Biology Reviews, 88(4), e00066-22.
18. Soliman, A. M., Hassan, E. A., Abdelkareem, A., & Farag, M. M. (2024). Characterization of Antibiotic Resistance Genes in Pseudomonas aeruginosa Isolates from Egyptian Patients. BBJ, 1049.
19. Salman, M. F., & ME, A. M. N. A. The effect of selenium nanoparticles on the expression of MexB gene of Pseudomonas aeruginosa Isolated from wound and burn infections. Iraqi JMS. 2024; 22 (1): 79-92. doi: 10.22578. IJMS, 22(10).)
20.Flores-Vega, V. R., Partida-Sanchez, S., Ares, M. A., Ortiz-Navarrete, V., & Rosales-Reyes, R. (2025). High-risk Pseudomonas aeruginosa clones harboring β-lactamases: 2024 update. Heliyon, 11(1).
21. Moitra, D. S., & Hazra, D. S. (2024). Dr. Shampa Das, Dr. Amit Kumar Majumdar, Dr. Prabir Kumar Ghosh and Dr. Arpita Paul Dutta, 2025. Antimicrobial Sensitivity Pattern of Pseudomonas Aeruginosa in Healthcare‐Associated Infections: Hospital‐Based Study. Res. J. Med. Sci, 19, 63-68.)
22. Vetrivel, A., Ramasamy, M., Vetrivel, P., Natchimuthu, S., Arunachalam, S., Kim, G.-S., & Murugesan, R. (2021). Pseudomonas aeruginosa Biofilm Formation and Its Control. Biologics, 1(3), 312-336. https://doi.org/10.3390/biologics1030019.
23. Ghafoor, A.; Hay, I.D.; Rehm, B.H.A. Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl. Environ. Microbiol. 2011, 77, 5238–5246
24. Abd El-Baky RM, Masoud SM, Mohamed DS, Waly NG, Shafik EA, Mohareb DA, et al. Prevalence and Some Possible Mechanisms of Colistin Resistance Among Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa. Infect Drug Resist. 2020; 13:323–32. https:// doi. org/ 10. 2147/ IDR. S2388 11.
25. Feng, L., Xu, M., Zeng, W., Zhang, X., Wang, S., Yao, Z., ... & Chen, L. (2022). Evaluation of the antibacterial, antibiofilm, and anti-virulence effects of acetic acid and the related mechanisms on colistin-resistant Pseudomonas aeruginosa. BMC microbiology, 22(1), 306.
26. Rozenblat M, Last O, Fisher S, Ziv M. Acetic acid treatment for toe web infection caused by Pseudomonas Aeruginosa combined with fungal infection: A case series of ten patients. Dermatol Ther. 2019;32(3): e12883.https:// doi. org/ 10. 1111/ dth. 12883.